Patents by Inventor Mark W. Trumbore

Mark W. Trumbore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stable, non-irritating topical formulations of hydroquinone
    Patent number: 10219995
    Abstract: Described herein are methods and compositions for increasing the efficacy and decreasing the irritancy of topical formulations of hydroquinone.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: March 5, 2019
    Assignee: SHAMROC, INC.
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Nupoor Devrajbhai Hirani
  • STABLE, NON-IRRITATING TOPICAL FORMULATIONS OF HYDROQUINONE
    Publication number: 20180235867
    Abstract: Described herein are methods and compositions for increasing the efficacy and decreasing the irritancy of topical formulations of hydroquinone.
    Type: Application
    Filed: April 23, 2018
    Publication date: August 23, 2018
    Inventors: Ronald M. GURGE, Mark W. TRUMBORE, Nupoor Devrajbhai HIRANI
  • Stable, non-irritating topical formulations of hydroquinone
    Patent number: 9949919
    Abstract: Described herein are methods and compositions for increasing the efficacy and decreasing the irritancy of topical formulations of hydroquinone.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: April 24, 2018
    Assignee: SHAMROC, INC.
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Nupoor Devrajbhai Hirani
  • Topical formulations for increasing the dermal concentration of hyaluronic acid
    Patent number: 9895393
    Abstract: Described herein are methods and compositions for increasing dermal concentrations of glycosaminoglycans (GAG), including hyaluronic acid. Exemplary methods involve a one-step protocol and a three-step protocol. Either method can be used over a 90-day treatment period.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: February 20, 2018
    Assignee: SHAMROC, INC.
    Inventors: Mark W. Trumbore, Drake D. Stimson, Ronald M. Gurge
  • Topical formulations for increasing the dermal concentration of hyaluronic acid
    Patent number: 9801807
    Abstract: Described herein are methods and compositions for increasing dermal concentrations of glycosaminoglycans (GAG), including hyaluronic acid. Exemplary methods involve a one-step protocol and a three-step protocol. Either method can be used over a 90-day treatment period.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: October 31, 2017
    Assignee: SHAMROC, INC.
    Inventors: Mark W. Trumbore, Drake D. Stimson, Ronald M. Gurge
  • TOPICAL FORMULATIONS FOR INCREASING THE DERMAL CONCENTRATION OF HYALURONIC ACID
    Publication number: 20170087178
    Abstract: Described herein are methods and compositions for increasing dermal concentrations of glycosaminoglycans (GAG), including hyaluronic acid. Exemplary methods involve a one-step protocol and a three-step protocol. Either method can be used over a 90-day treatment period.
    Type: Application
    Filed: December 8, 2016
    Publication date: March 30, 2017
    Inventors: Mark W. TRUMBORE, Drake D. STIMSON, Ronald M. GURGE
  • High oil-content emollient aerosol foam compositions
    Patent number: 9370487
    Abstract: Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: June 21, 2016
    Assignee: Precision Dermatology, Inc.
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Lisa Chin, Poonam S. Hirani
  • TOPICAL TREATMENT OF LOCALIZED SCLERODERMA
    Publication number: 20160120865
    Abstract: Disclosed are compositions and formulations for topical administration that contain a tyrosin kinase inhibitor, such as imatinib or nilotinib. The topical compositions or formulations are useful in treating scleroderma.
    Type: Application
    Filed: May 30, 2014
    Publication date: May 5, 2016
    Inventors: Mark W. Trumbore, Martin P. Redmon, Robert Alan Lafyatis, Pinaki Ranjan Majhi
  • Topical pharmaceutical foam composition
    Patent number: 9278066
    Abstract: A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an oil-in-water emulsion which contains one or more hydrofluoroalkane (HFA) propellants and one or more keratolytic agents. The keratolytic agent may be present in either phase of the emulsion or dispersed in the emulsion. The oil phase may consist at least in part of the HFA propellant. The foam is stable on the skin for at least 5 minutes at body temperature and disappears into the skin upon rubbing or after prolonged standing. The formulations may not contain additional co-solvents or non-HFA co-propellants. The formulations demonstrate reduced intensity of the odor and/or color associated with the keratolytic agent(s) as compared to conventional formulations containing keratolytic agents.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: March 8, 2016
    Assignee: Precision Dermatology, Inc.
    Inventors: Mark W. Trumbore, Ronald M. Gurge, Jane C. Hirsh
  • STABLE, NON-IRRITATING TOPICAL FORMULATIONS OF HYDROQUINONE
    Publication number: 20150290121
    Abstract: Described herein are methods and compositions for increasing the efficacy and decreasing the irritancy of topical formulations of hydroquinone.
    Type: Application
    Filed: June 23, 2015
    Publication date: October 15, 2015
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Nupoor Devrajbhai Hirani
  • Stable, non-irritating topical formulations of hydroquinone
    Patent number: 9089506
    Abstract: Described herein are methods and compositions for increasing the efficacy and decreasing the irritancy of topical formulations of hydroquinone.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: July 28, 2015
    Assignee: Precision Dermatology, Inc.
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Nupoor Devrajbhai Hirani
  • Cyclodextrin-based microemulsions, and dermatological uses thereof
    Patent number: 9018236
    Abstract: Described herein are cyclodextrin-stabilized microemulsion systems useful for increasing the solubility, stability, bioavailability, or safety of an active agent for delivery to the skin. The microemulsions may reduce the occurrence of skin irritation or odor upon application.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 28, 2015
    Assignee: Precision Dermatology, Inc.
    Inventors: Mark W. Trumbore, Pinaki Ranjan Majhi, Dinen Divyang Shah
  • High Oil-Content Emollient Aerosol Foam Compositions
    Publication number: 20140328769
    Abstract: Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.
    Type: Application
    Filed: July 18, 2014
    Publication date: November 6, 2014
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Lisa Chin, Poonam S. Hirani
  • Controlling the Bioavailability of Active Ingredients in Topical Formulations
    Publication number: 20140243300
    Abstract: Described are methods and compositions for tuning the bioavailability of an active agent, such as a corticosteroid, in a topical formulation.
    Type: Application
    Filed: February 28, 2014
    Publication date: August 28, 2014
    Applicant: Precision Dermatology, Inc.
    Inventors: Mark W. Trumbore, Pinaki R. Majhi, Neha Aggarwal
  • Stable, Non-Irritating Topical Formulations of Hydroquinone
    Publication number: 20140243423
    Abstract: Described herein are methods and compositions for increasing the efficacy and decreasing the irritancy of topical formulations of hydroquinone.
    Type: Application
    Filed: February 27, 2013
    Publication date: August 28, 2014
    Applicant: Precision Dermatology, Inc.
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Nupoor Devrajbhai Hirani
  • Topical Formulations of Corticosteroids with Enhanced Bioavailability
    Publication number: 20140243299
    Abstract: Described herein are methods and compositions for increasing the bioavailability of a corticosteroid, such as hydrocortisone 17-butyrate, in a topical formulation.
    Type: Application
    Filed: February 28, 2014
    Publication date: August 28, 2014
    Applicant: Precision Dermatology, Inc.
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Pinaki R. Majhi
  • High oil-content emollient aerosol foam compositions
    Patent number: 8784780
    Abstract: Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: July 22, 2014
    Assignee: Precision Dermatology, Inc.
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Lisa Chin, Poonam S. Hirani
  • Topical Formulations for Increasing the Dermal Concentration of Hyaluronic Acid
    Publication number: 20140170251
    Abstract: Described herein are methods and compositions for increasing dermal concentrations of glycosaminoglycans (GAG), including hyaluronic acid. Exemplary methods involve a one-step protocol and a three-step protocol. Either method can be used over a 90-day treatment period.
    Type: Application
    Filed: December 12, 2013
    Publication date: June 19, 2014
    Applicant: Precision Dermatology, Inc.
    Inventors: Mark W. Trumbore, Drake D. Stimson, Ronald M. Gurge
  • Foamable Benzoyl Peroxide Compositions for Topical Administration
    Publication number: 20140140937
    Abstract: Described herein are benzoyl peroxide compositions useful in the treatment of acne and other skin conditions, which exhibit enhanced stability, even under accelerated conditions. The compositions also exhibit reduced color formation, reduced irritation, and enhanced moisturizing properties. They can be formulated into a topical aerosol foam with inert, non-flammable propellants, such as hydrofluoroalkanes, and may be used in cosmetics or pharmaceuticals. Additionally, methods of formulating these compositions are described.
    Type: Application
    Filed: January 27, 2014
    Publication date: May 22, 2014
    Applicant: Precision Dermatology, Inc.
    Inventors: Ronald M. Gurge, Mark W. Trumbore
  • Topical Pharmaceutical Foam Composition
    Publication number: 20140134112
    Abstract: A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an oil-in-water emulsion which contains one or more hydrofluoroalkane (HFA) propellants and one or more keratolytic agents. The keratolytic agent may be present in either phase of the emulsion or dispersed in the emulsion. The oil phase may consist at least in part of the HFA propellant. The foam is stable on the skin for at least 5 minutes at body temperature and disappears into the skin upon rubbing or after prolonged standing. The formulations may not contain additional co-solvents or non-HFA co-propellants. The formulations demonstrate reduced intensity of the odor and/or color associated with the keratolytic agent(s) as compared to conventional formulations containing keratolytic agents.
    Type: Application
    Filed: January 21, 2014
    Publication date: May 15, 2014
    Applicant: Precision Dermatology, Inc.
    Inventors: Mark W. Trumbore, Ronald M. Gurge, Jane C. Hirsh